# Comparative Efficacy of Cemiplimab to Historical Standard of Care in France

> **NCT05302297** · — · COMPLETED · sponsor: **Sanofi** · enrollment: 305 (actual)

## Conditions studied

- Cancer/Squamous Cell Carcinoma of Skin

## Interventions

- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT05302297
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-17
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2022-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05302297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05302297, "Comparative Efficacy of Cemiplimab to Historical Standard of Care in France". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05302297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*